• linkedin
  • Increase Font
  • Sharebar

    Aflibercept shows macular perfusion gains in VISTA subanalysis


    Focus on subretinal changes

    The results presented by Dr. Dhoot focused on subretinal changes through week 100, as well as visual outcomes with and without macular perfusion.

    “We evaluated visual and anatomic outcomes among patients with and without macular nonperfusion and considered if they were impacted by a change in the macular perfusion,” Dr. Dhoot said.

    The subanalysis included 452 patients from the VISTA trial. Patients with missing or ungradable perfusion data or those receiving rescue medications were not included.

    Patients had fluorescein angiograms performed during the VISTA trial at baseline and at weeks 24, 52, 72, and 100. Angiograms were graded by masked independent graders at a reading center, and the angiograms were divided into quadrants at the intersecting optic nerve head.

    “A quadrant was determined to be nonperfused with any presence of nonperfusion,” Dr. Dhoot said.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available

    Latest Tweets Follow

    var script= ' ';